CLOUDWAYS
Cloudways (cloudways.com), the leading cloud hosting provider focused on simplicity, flexibility, and performance, announces significant customer momentum ahead of their presence at WordCamp Europe. Cloudways’ announcements at WordCamp Europe include SafeUpdates (in beta), new automations that manage WordPress updates at scale, and partnership with Astra Pro, a collaboration allowing users to build websites faster and easier than ever before.
Cloudways supports over 70k customers and 500K+ websites and was recently rated by G2 as the best cloud hosting company for SMBs with a rating of 4.8 out of 5. Additionally, Cloudways has strengthened its executive team with the hire of ex-Microsoft executive Paul Haverstock as VP of Engineering, Bluehost executive Suhaib Zaheer as COO, and AWS executive Tom Erskine as CMO. Cloudways has significantly grown in size to more than 280 employees, with its global mindset reflected in an employee base coming from 20+ countries.
Cloudways focuses on giving agencies, SMBs, e-commerce providers, and individuals a hassle-free, premium experience to help them grow their business with both peace of mind and improved productivity. The Cloudways platform features >99.9% uptime, fast page load times, pro-active app monitoring, dedicated workflows, leading security with add-ons from Cloudflare, and 24/7 premium support. Great value and flexibility are also key platform features with pay-as-you-go plans offered from cloud providers including AWS, Google Cloud, Linode, Vultur, and Digital Ocean and a choice of 65+ Data Center locations.
SafeUpdates, which is being launched in beta, is Cloudways’ newest feature and will enable agencies and developers to update their WordPress websites both automatically and on demand. The workflow secures a backup, performs advanced visual regression testing and performance checks on both staging and live, and then deploys selected updates to production or automatically rolls back the changes in case of any issues. SafeUpdates allows agencies and developers to automate their work, focus on their business, and upsell maintenance services with confidence.
Cloudways’ partnership with Astra Pro is part of a series of collaborations the company has made in recent months to enhance WordPress simplicity and ensure maximum performance and security on its platform. Cloudways has worked closely with Cloudflare, OceanWP, Divi, and OCP among others to offer a seamless, no-code digital experience for agencies and developers to build and secure WordPress websites.
“Cloudways is both growing as a company and building significant momentum in the cloud hosting industry,” said Aaqib Gadit, Co-Founder and CEO of Cloudways. “The recent addition of Suhaib, Tom, and Paul to our leadership team shows the growth plans and ambition we have for Cloudways. At Cloudways, we are deeply focused on being a trusted partner to our customers and are continually innovating to save them both time and money while delivering a great user experience.”
To learn more, visit Cloudways’ booth at WordCamp Europe at https://www.cloudways.com/en/wordcamp-europe.php
About Cloudways:
Founded in 2012, Cloudways is an intuitive, one-click managed cloud hosting platform that hosts over 50,000 servers globally. G2’s Best Managed Hosting Provider for 2021, the platform lets users host WordPress and WooCommerce websites on top of a variety of cloud-hosting providers, including Google Cloud, Amazon Web Services, DigitalOcean, Vultr, and Linode. The platform features a web app management function that easily launches cloud servers for the deployment of WordPress, Magento, and PHP. Visit the company website at https://www.cloudways.com/en/about_us.php
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005120/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom